CYP2E1 and injury: Specifically, bortezomib was reported to decrease hepatocyte nuclear factor−1α-induced promoter activation of cytochrome P450 2E1 (CYP2E1) and induced endoplasmic reticulum stress, thereby significantly down-regulating CYP2E1 expression and alleviating APAP-, CCl4-, and thioacetamide-induced liver injury in mice (Park et al., 2016).